Polar Asset Management Partners’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Polar Asset Management Partners’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,165,086	Closed	-$30.2K	–	924
2024 Q3	$30.2K	Hold	2,165,086	–	–	﹤0.01%	580
2024 Q2	$75.7K	Hold	2,165,086	–	–	﹤0.01%	508
2024 Q1	$119K	Hold	2,165,086	–	–	﹤0.01%	512
2023 Q4	$140K	Hold	2,165,086	–	–	﹤0.01%	500
2023 Q3	$509K	Hold	2,165,086	–	–	0.01%	497
2023 Q2	$258K	Hold	2,165,086	–	–	﹤0.01%	588
2023 Q1	$88.8K	Hold	2,165,086	–	–	﹤0.01%	705
2022 Q4	$108K	Hold	2,165,086	–	–	﹤0.01%	805
2022 Q3	$123K	Hold	2,165,086	–	–	﹤0.01%	883
2022 Q2	$195K	Buy	2,165,086 +1,422,523	+192%	+$315K	﹤0.01%	838
2022 Q1	$267K	Hold	742,563	–	–	﹤0.01%	743
2021 Q4	$371K	Buy	+742,563	New	+$419K	﹤0.01%	919

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Polar Asset Management Partners's CLDI.WS Position: Q4 2024 in Review

Polar Asset Management Partners sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 2,165,086 shares — an estimated $30.2K sold.

Polar Asset Management Partners first reported a position in CLDI.WS in Q4 2021 and held it in 12 quarters. The position peaked at $509K in Q3 2023. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Polar Asset Management Partners reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Polar Asset Management Partners sold 2,165,086 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $30.2K.
Polar Asset Management Partners first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 12 quarters.
Polar Asset Management Partners's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $509K in Q3 2023.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Polar Asset Management Partners's 13F filing for Q4 2024, filed 14 Feb 2025.